Details of the Drug

General Information of Drug (ID: DMX4938)

Drug Name
SDZ-LAP-977
Synonyms SDZ-281-977
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Discontinued in Phase 2 [1]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 316.3
Logarithm of the Partition Coefficient (xlogp) 4.1
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
Chemical Identifiers
Formula
C18H20O5
IUPAC Name
methyl 5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxybenzoate
Canonical SMILES
COC1=CC(=C(C=C1)OC)CCC2=CC(=C(C=C2)O)C(=O)OC
InChI
InChI=1S/C18H20O5/c1-21-14-7-9-17(22-2)13(11-14)6-4-12-5-8-16(19)15(10-12)18(20)23-3/h5,7-11,19H,4,6H2,1-3H3
InChIKey
GZOFTOHENYHNMS-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
9818362
ChEBI ID
CHEMBL129856
CAS Number
150779-71-8
TTD ID
D0D5CJ
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase (PTK) TTJSQEF NOUNIPROTAC Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004738)
2 Structure-activity relationship studies on a novel class of antiproliferative agents derived from Lavendustin A. Part I: Ring A modifications. Bioorg Med Chem. 2008 Aug 15;16(16):7552-60.